| Literature DB >> 34278421 |
Sara Carrillo de Albornoz1, Kah-Ling Sia1, Anthony Harris1.
Abstract
BACKGROUND: The COVID-19 pandemic has focussed attention on models of healthcare that avoid face-to-face contacts between clinicians and patients, and teleconsultations have become the preferred mode of primary care delivery. However, the effectiveness of remote consultations in this setting remains unclear.Entities:
Keywords: Mental health; primary care; remote consultation; teleconsultation; telehealth; telemedicine
Mesh:
Year: 2022 PMID: 34278421 PMCID: PMC8344904 DOI: 10.1093/fampra/cmab077
Source DB: PubMed Journal: Fam Pract ISSN: 0263-2136 Impact factor: 2.267
Figure 1.Flow diagram of the study selection process
Summary characteristics of included studies of teleconsultations in primary care and allied health
| Main Diagnosis | Study ID | Design | Risk of Bias | Country | Population | Therapy type | Sessions, | Attrition | Key outcomes | Results |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Cancer | Collins 2017 ( | Non-randomised comparative study | High | Australia | Patients aged 32–77 with head and neck cancer; | Model of care for reviews with speech pathology, nutrition and dietetics | Average 4.3 sessions/patient over 8 months | 6.7% (inappropriate technology) | Number and duration of appointments per person and total service cost | TM significantly reduced the number and duration of appointments required until discharge, and had significantly lower cost per patient. |
| Acute nonurgent conditions | Gordon 2017 ( | Cross-sectional matched-control retrospective study | Some concerns | USA | Patients aged ≤ 65 with acute nonurgent conditions; | Retail health clinics, urgent care centres, emergency departments, or primary care physicians | Index episode | NR | Healthcare utilisation during and following the index visit and cost of care | TM reduces health are utilisation (lab tests, imaging) and lower cost per episode including medical and pharmacy cost compared to F2F. |
| Disability | McCarthy 2020 ( | Non-randomised comparative study | High | Australia | Caregivers aged ≥18 of deaf or hard hearing child (aged < 8); | Family-Centred Early Intervention | Weekly/ fortnightly/ monthly sessions over >6 months | TM = 69% | Parental self- efficacy and session frequency | No significant difference on caregiver’s perception of self-efficacy and session frequency between TM and F2F. |
| Major diagnosis (ADGs | McGrail 2017 ( | Cross-sectional matched-control retrospective study | High | Canada | Patients aged ≥18 with major ADGs | Primary care visit | Index episode plus 3 years follow-up | NR | Cost of primary care visit | TM is significantly more likely to be used by younger patients and physicians. TM reduces primary care costs but benefit is significantly associated with seeing a known provider. |
| Smoking cessation | Nomura 2019 ( | RCT | Some concerns | Japan | Adults with nicotine- dependence; | Counselling (smoking cessation) | 5 sessions over 12 weeks | 2.6% (withdrew consent, lost to f/up) | continuous abstinence rate (CAR) | TM is non-inferior to F2F for CAR from weeks 9 to 12. No significant difference between TM and F2F in reduction of nicotine dependence and cravings. |
| Respiratory infection | Shi 2018 ( | Cross-sectional matched-control retrospective study | Some concerns | USA | Patients aged 18–64 with acute respiratory infections; | Primary care visit | Index episode plus 21 days follow-up | NR | Quality of care | Compared to F2F, TM had significant but not clinically meaningful (small) improvement in some measures of quality of care (antibiotic use). On other quality measures F2F performed better. |
|
| ||||||||||
| Obesity | Harrigan 2016 ( | RCT | High | USA | Breast cancer survivors with BMI≥25; | Counselling (weight loss) | 11 sessions over 6 months | TM = 53% | Body composition (height and weight) | No significant difference between TM and F2F for weight loss |
| Malnutrition | Lindegaard Pedersen 2017 ( | RCT | Some concerns | Denmark | Patients aged 75–103 with malnourishment or risk of malnutrition; | Counselling (nutrition) | 3 sessions over 4 weeks | TM = 22 (32%) | Readmissions at 30 and 90 days after discharge | No significant difference between TM and F2F for readmissions |
| Smoking cessation | Ramon 2013( | RCT | Some concerns | Spain | Smokers aged ≥18 years; | Counselling (smoking cessation) | 7 sessions over 52 weeks | TM = 70 (35%) | Continuous abstinence rate (CAR) | F2F had significantly higher CAR at 52 weeks compared to TM. |
| General | McKinstry 2011 ( | Non-randomised comparative study | High | Scotland | Patients from 11 GPs; | Primary care visit | Individual visit plus 9 days follow-up | 18% | Prospective- Retrospective Memory Questionnaire (PRM-Q) | TM and F2F were comparable in accuracy of recall (for single and multiple problem consultations). Significantly more repetition of advice in enhancing patient recall was given in F2F. |
| Post-partum | Seguranyes 2014 ( | RCT | Some concerns | Spain | Post-partum patients; | Post-natal care | Any over 6 weeks post-partum | TM = 228 (25%) | Number and type of consults, health centre visits, infant feeding and maternal satisfaction with care | Significantly higher number of consults made by TM than F2F. TM group had significantly few visits to the health centre. TM and F2F comparable in prevalence of breast feeding and maternal satisfaction with care |
F2F, face-to-face; NR, not reported; RCT, randomised control trial; TM, telemedicine
aTotal sample included 52 751 adults, 7194 child ( < 18 years).
bIndex date defined as the date of the first outpatient or ED claim in a 3-week period for 11 of the most commonly diagnosed conditions.
c8 major aggregated diagnosis group using the Johns Hopkins’ adjusted clinical group, which included, mental disorders, diseases of respiratory system, diseases of musculoskeletal system, diseases of nervous system, metabolic diseases and immunity disorders, infections, diseases of circulatory system, disease of genitourinary system.
dnumber of health visits; number of patients not reported.
epatients could make videoconferencing or telephone consults.
fThe main reason for lost to follow-up in the TM group: failure to attend final visit, failure to register for skype and lack of internet access; and in the F2F group: failure to attend final visit. The study recruited 134 (TM = 113 and F2F = 21) to compensate for the subject lost.
Effectiveness of teleconsultations in primary care
| Outcome measures | N patients | TM, mean (SD or 95% CI) | F2F, mean (SD or 95% CI) | Treatment difference, mean (95% CI) | Follow up | Study ID |
|---|---|---|---|---|---|---|
|
| ||||||
| Number of appointments per person | TM = 15 | 3.4 (1.15) | 5.3 (2.10) |
| 8 months | Collins 2017 ( |
| Duration (minutes) of appointments per person | 23 (6.0) | 27.5 (6.2) |
| |||
| Total societal cost per person | $143 (46) | $317 (176) | $US 174, | |||
| % outpatient visits after index visit | TM = 4635 | 28.1% | 28.1% |
| 3 weeks | Gordon 2017 ( |
| % hospitalisation after index visit | 0.2% | 0.4% |
| |||
| Adjusted | $200 | $288 |
| |||
| SPICE parental self-efficacy subscales (PSEDU, PSESL, PIDU, PISL) | TM = 41 | 5.56 (0.97), 6.03 (0.75), 5.68 (0.88), 5.83 (0.71) | 5.38 (1.07), 5.90 (0.99), 5.74 (0.93), 5.77 (0.83) | 0.18, 0.13, –0.06, 0.06 | >6 months | McCarthy 2020 ( |
| % weekly session frequency | 68.3% | 67% |
| |||
| Cost of primary care (GP) visit | TM = 5441 | – | – | –$CAN 3.79, | 3 years | McGrail 2017 ( |
| Cost of primary care visit with known known provider | –‘ | – | –$CAN 8.68, | |||
| Continuous abstinence rate from weeks 9 to 12 | TM = 58 | 81.0 (38.8) | 78.9 (40.8) | 2.1 (–12.8, 17.0) | 12 weeks | Nomura 2019 ( |
| Continuous abstinence rate from weeks 9 to 24 | 74.1 (43.4) | 71.9 (45.3) | 2.2 (–14.0, 18.4) | 24 weeks | ||
| % Any antibiotic use | TM = 38,839 | 52% | 53% | 1%, | 21 d (3 weeks) | Shi 2018 ( |
| % Guideline antibiotic management | 62% | 60% | 2%, | |||
|
| ||||||
| Change in body weight (kg) | TM = 34 | –4.8 (–6.5, –3.1) | –5.6 (–7.1, –4.1) |
| 6 months | Harrigan 2016 ( |
| –6.3 (–9.9, –2.6) | –5.6 (–8.0, –3.3) |
| 12 months | |||
| HR hospital readmission at 30 days | TM = 68 | 0.6 (0.3–1.3) | 0.4 (0.2–0.9) |
| 30 days (1 months) | Lindegaard Pedersen 2017 ( |
| HR hospital readmission at 90 days | 0.7 (0.4–1.3) | 0.4 (0.2–0.8) |
| 90 days (3 months) | ||
| Continuous abstinence rate from weeks 2 to 24 | TM = 201 | 30.1 | 42.3 |
| 24 weeks | Ramon 2013 ( |
| Continuous abstinence rate from weeks 2 to 52 | 20.1 | 27.9 |
| 52 weeks | ||
| % Accurate recall | TM = 50 | 82% | 68% | 14% (–2%, 27%) | 13 days | McKinstry 2011 ( |
| % Clinician approach (advice repetition) enhance recall | 28% | 47% |
| |||
| Number of post-partum consults | TM | 2.74 (1.47) | 1.22 (0.75) |
| 6 weeks | Seguranyes 2014 ( |
| Number of health centre visits | 1.0 (0.85) | 1.17 (0.74) |
| |||
| Prevalence of breastfeeding | 64.5% | 65.4% |
| |||
| Satisfaction with midwifery care | 4.77 (0.49) | 4.76 (0.56) |
|
CLBP, Chronic low back pain; F2F, face-to-face; HR, hazard ratio; PIDU, Parental Involvement (Device Use); PISL, Parental Involvement (Speech and Language Development); PSEDU, Parental Self-Efficacy (Device Use); PSESL, Parental Self-Efficacy (Speech and Language Development); PD, Pulmonary disease; SPICE, Scale of Parental Involvement and Self-Efficacy; SPL, sound pressure level; TM, telemedicine; d, day; m, month; w, week
aCosts adjusted for age categories and baseline comorbidities.
bMean values with were measured at the specified follow-up times reported in the table
cnumber of health visits; number of patients not reported.
dpatients could make videoconferencing or telephone consults.
Summary characteristics of included studies of teleconsultations in patients with mental health conditions
| Main Diagnosis | Study ID | Design | Risk of Bias | Country | Population | Therapy type | Sessions, | Attrition | Key outcomes | Results |
|---|---|---|---|---|---|---|---|---|---|---|
| Video consultation | ||||||||||
| Depression | Choi 2014 ( | RCT | High | USA | Low income older adults (50–64 years) | Problem-solving therapy | 6 sessions |
| Depression (HAMD) | • Improvement in depression in both groups, no significant difference |
| Choi 2014b ( | RCT | High | USA | Low income older adults (>50 years) | Problem-solving therapy | 6 sessions |
| Depression (HAMD) and disability (WHODAS) | • Improvement in depression and disability in both groups | |
| Depression (DSM- IV criteria for major depressive disorder) | Egede 2015 ( | RCT (non-inferiority) | Low | USA | Military veterans (>58 years) | Behavioural activation | 8 sessions | TM = 20 (16.6%) | Depression (GDS, BDI) | • TM is non-inferior to F2F for the treatment of depression |
| Egede 2016 ( | Low | Quality of life | • No significant differences in SF-36 or satisfaction with treatment between TM and F2F at 12months | |||||||
| Egede 2018 ( | RCT | Low | USA | Military veterans (>58 years) with type 2 diabetes | Behavioural activation | 8 sessions | NR | Type 2 diabetes control | • TM was superior to F2F treatment to lower HbA1C | |
| Depressive disorder (minor or major) | Luxton 2016 ( | RCT (non-inferiority) | High | USA | Military members and veterans (18–65 years) | Behavioural activation | 8 sessions | TM = 22 (35.5%) | Depression | • Significant reductions in depression in both group |
| PTSD | Acierno 2016 ( | RCT (non-inferiority) | Some concerns | USA | Military veterans (mean age 45 years) | Behavioural Activation and Therapeutic Exposure | 8 sessions | 48 did not complete at least 5 sessions | PTSD | • TM was non-inferior to F2F treatment to reduce PTSD and depression symptoms at all time points |
| PTSD | Acierno 2017 ( | RCT (non-inferiority) | Some concerns | USA | Military veterans (mean age 42 years) | Prolonged exposure | 10 to 12 sessions | TM = 32.8% | PTSD | • TM was non-inferior to F2F treatment to reduce PTSD at all time points. |
| PTSD | Maieritsch 2016 ( | RCT | High | USA | Military veterans (mean age 31 years) | Cognitive processing therapy | 10 sessions | TM = 20 (44.4%) | PTSD | • Significant decreases in depression and PTSD symptoms in both arms, but the difference between groups was not calculated due to high attrition |
| Medically unexplained pain | Chavooshi 2017 ( | RCT | Some concerns | Iran | Adults aged 18–45 years with medically unexplained pain for ≥6 months | Intensive short- term dynamic psychotherapy | 16 sessions | TM = 9 (23%) | Pain intensity | • F2F treatment led to significantly greater improvements in pain intensity, depression and anxiety compared to TM |
| Opioid abuse | King 2014 ( | RCT | High | USA | Outpatients attending addiction treatment services | Motivated Stepped Care Counseling | 12 weeks with number of sessions: | TM = 2 (8.3%) | Client satisfaction | • Treatment satisfaction and therapeutic alliance was high and similar in both groups |
| Telephone consultation | ||||||||||
| Depression | Alcantara 2016 ( | RCT | High | USA & Puerto Rico | Low-income Latinos (≥18 years) in primary care | Engagement and Counselling for Latinos (ECLA); including psychoeducation, behavioural activation, cognitive reframing, and motivational interviewing | 6 to 8 sessions | TM = 17 (31.0%) | Worry reductions (PSWQ) | • Significantly larger worry reductions in TM vs. F2F |
| Depression (Major depression) | Fann 2015 ( | RCT | High | USA | Patients with traumatic brain injury (mean age 45.8 years) | Cognitive behavioural therapy | 12 sessions over 12 weeks | TM = 5 (12.5%) | Depression | • No significant differences between TM and F2F for depression severity or therapeutic alliance |
| Depression | Kalapatapu 2014 ( | RCT | Low | USA | Patients with problematic alcohol use in primary care (mean age 42–45 years) | Cognitive behavioural therapy | 18 sessions over 18 weeks | TM = 26.0% F2F = 24.5% | Depression | • No significant difference between TM and F2F at any time point for depression outcomes |
| Mohr 2012 ( | RCT (non-inferiority) | Low | USA | Patients in primary care (mean age 47 years) | Cognitive behavioural therapy | 18 sessions over 18 weeks | TM = 34 (20.9%) | Depression | • TM improves adherence | |
| Stiles-Shields 2014 ( | Low | Therapeutic alliance | • No significant differences in therapeutic alliance | |||||||
| Cancer | Watson 2017 ( | RCT | High | UK | Cancer patients referred to psychological care (mean age 48–52 years) | Cognitive behavioural therapy | Up to 8 sessions over 12 weeks | TM = 17 (28.3%) | Depression | • No significant differences from baseline to Week 8 in depression and anxiety |
F2F, face-to-face, PTSD, post-traumatic stress disorder, RCT, randomised control trial, TM, telemedicine
aAttrition was due mostly to deteriorating health problems that resulted in hospitalization, nursing home placement, and death
bThird patient group was telephone support, but not included as the intervention given to this group differed from the others.
cThird patient group was usual care, including rehabilitation and primary care services (without cognitive behavioural therapy)
Effectiveness of teleconsultations in patients with mental health conditions
| Outcome measures | N patients | TM, mean (SD or 95% CI) | F2F, mean (SD or 95% CI) | Treatment difference; TM vs. F2F, mean (95% CI) | Follow up | Study ID |
|---|---|---|---|---|---|---|
|
| ||||||
| HAMD, mean (SD) | TM = 43, F2F = 42 | 13.92 (1.18) | 14.44 (1.19) | t = −0.31, | 12 weeks (~3 months) | Choi 2014 ( |
| 13.37 (1.18) | 14.80 (1.12) | t = −0.90, | 24 weeks (~6 months) | |||
| TM = 56, F2F = 63 | 13.68 (1.00) | 14.08 (0.94) | t = –0.06, | 12 weeks (3 months) | Choi 2014b ( | |
| 12.38 (0.85) | 14.12 (0.80) | t = –1.49, | 24 weeks (6 months) | |||
| 11.08 (1.07) | 14.16 (0.99) | t = –2.11, | 36 weeks (9 months) | |||
| BDI response, n (%), [95% CI] | TM = 120, F2F = 121 | 27 (22·54%), [15.40, 29.69] | 26 (21·49%), [14.72, 28.25] | 1·05% (–8·30, 10·41) | 12 months | Egede 2015 ( |
| GDS response, n (%), [95% CI] | 25 (20·96%), [14.45, 27.47] | 23 (19·30%), [13.29, 25.31] | 1·66% (–7·20, 10·52) | 12 months | ||
| BHS, mean (SD) | TM = 45, F2F = 42 | 4.89 (4.64) | 4.43 (4.94) | 0.40 (0.12, 0.68) | 8 weeks (~2 months) | Luxton 2016 ( |
| TM = 42, F2F = 36 | 5.21 (5.10) | 5.53 (5.97) | 0.28 (–0.01, 0.58) | 3 months | ||
| BDI-II, mean (SD) | TM = 45, F2F = 42 | 13.82 (12.02) | 11.74 (12.08) | 0.36 (0.06, 0.66) | 8 weeks (~2 months) | |
| TM = 42, F2F = 36 | 14.76 (12.89) | 15.00 (12.61) | 0.16 (–0.16, 0.48) | 3 months | ||
| BDI-II | TM = 131, F2F = 134 | NR | NR | 0.89 (NI) | Post-treatment (~8–9 weeks) | Acierno 2016 ( |
| 1.18 (NI) | 3 months | |||||
| –0.29 (NI) | 6 months | |||||
| BDI-II | TM = 64, F2F = 68 | NR | NR | –2.4 (–6.3, 1.5) | Post-treatment (~12 weeks) | Acierno 2017 ( |
| –2.0 (–5.7, 1.6) | 3 months | |||||
| –0.3 (–4.1, 3.6) | 6 months | |||||
| BDI-II, mean (SE) | TM = 45, F2F = 45 | 19.26 (2.6) | 20.99 (2.7) | NR | Post-treatment (~10 weeks) | Maieritsch 2016 ( |
| 17.08 (2.2) | 17.29 (2.3) | NR | 12 weeks | |||
| DASS depression, mean (SD) | TM = 39, F2F = 42 | 14.28 (3.9) | 7.5 (2.3) | < 0.001 | Post-treatment (16 weeks) | Chavooshi 2017 ( |
| 13.31 (4.5) | 6.5 (3.5) | < 0.001 | 12 months | |||
| WHODAS, mean (SD)’ | TM = 56, F2F = 63 | 29.72 (1.25) | 30.13 (1.19) | t = 0.24, | 12 weeks (3 months) | Choi 2014b ( |
| 29.38 (1.12) | 30.60 (1.05) | t = –0.80, | 24 weeks (6 months) | |||
| 29.04 (1.32) | 31.07 (1.24) | t = –1.12, | 36 weeks (9 months) | |||
| PCL-M | TM = 131, F2F = 134 | NR | NR | –0.11 (NI) | Post-treatment (~8–9 weeks) | Acierno 2016 ( |
| –1.84 (NI) | 3 months | |||||
| –0.66 (NI) | 6 months | |||||
| PCL-M | TM = 64, F2F = 68 | NR | NR | −3.2 (−8.6, 2.1) | Post-treatment (~12 weeks) | Acierno 2017 ( |
| −2.8 (−7.6 to 2.0) | 3 months | |||||
| 0.03 (−4.9 to 5.0) | 6 months | |||||
| PCL, mean (SE) | TM = 45, F2F = 45 | 48.07 (2.3) | 45.13 (2.5) | NR | Post-treatment (~10 weeks) | Maieritsch 2016 ( |
| 46.17 (2.2) | 45.94 (2.3) | NR | 12 weeks | |||
| NPRS, mean (SD) | TM = 39, F2F = 42 | 6.15 (2.25) | 4.22 (1.65) |
| Post-treatment (16 weeks) | Chavooshi 2017 ( |
| 6.36 (1.78) | 4.17 (1.14) |
| 12 m | |||
| DASS anxiety, mean (SD) | TM = 39, F2F = 42 | 15.9 (3.8) | 6.8 (3.4) | < 0.001 | Post-treatment (16 weeks) | |
| 15.3 (5.1) | 6.5 (5.3) | < 0.001 | 12 months | |||
| HbA1C, mean | TM = 43, F2F = 47 | 6.875 | 7.698 | –0.82 (–1.41, –0.24) | 12 months | Egede 2018 ( |
|
| ||||||
| HAMD, mean (SD) | TM = 40, F2F = 18 | 13.3 (5.6) | 12.7 (7.2) | 0.60 (–3.15, 4.35) | 8 weeks (2 months) | Fann 2015 ( |
| 11.5 (6.2) | 11.9 (6.1) | –0.40 (–3.81, 3.01) | 16 weeks (4 months) | |||
| 10.4 (6.4) | 12.1 (7.8) | –1.70 (–5.81, 2.41) | 24 weeks (6 months) | |||
| TM = 45 F2F = 47 | 12.8 (9.2) | 11.8 (7.2) |
| Post-treatment (18 weeks) | Kalapatapu 2014 ( | |
| TM = 44 F2F = 47 | 13.4 (8.3) | 10.4 (6.0) |
| 3 months follow-up | ||
| TM = 42 F2F = 46 | 13.5 (8.7) | 10.4 (6.0) |
| 6 months | ||
| TM = 152 F2F = 141 | 13.58 (12.42 to 14.74) | 12.51 (11.22 to 13.81) | 1.07 (−0.63, 2.76), | Post-treatment (18 weeks) | Mohr 2012 ( | |
| TM = 146 F2F = 136 | 14.58 (13.45 to 15.71) | 12.33 (11.01 to 13.64) | 2.25 (0.52, 3.99), | 3 months | ||
| TM = 134 F2F = 136 | 15.06 (13.84 to 16.27) | 12.14 (10.84 to 13.45) | 2.91 (1.20, 4.63) | 6 months | ||
| HADS-depression, change from baseline (SD) | TM = 43 F2F = 35 | 1.86 (3.29) | 2.31 (4.40) | –0.45 (–2.19, 1.28) | 8 weeks (2 months) | Watson 2016 ( |
| HADS-anxiety, change from baseline (SD) | TM = 43 F2F = 35 | 2.02 (3.54) | 2.11 (4.54) | –0.09 (–1.91, 1.73) | 8 weeks (2 months) | |
| PSWQ, mean change from baseline | TM = 87, F2F = 84 | –7.83 (11.45) | –6.73 (12.23) |
| 4 months | Alcantara 2016 ( |
BDI, Beck depression inventory, BHS, Beck Hopelessness scale, DASS, Depression anxiety stress scale, GDS, Geriatric depression scale, HADS, Hospital anxiety and depression scale, HAMD, Hamilton rating scale for depression, NI, non-inferior, NPRS, Numeric pain rating scale, NR, not reported, PCL-M, Post-traumatic stress disorder checklist-military, PSWQ, Penn State Worry Questionnaire, WHODAS, World health organisation disability assessment schedule
aMean values with were measured at the specified follow-up times reported in the table
bStandardised difference using the baseline standard deviation; 90% Confidence interval used to evaluate non-inferiority
cCI not reported in the text, assessed as non-inferior (lower bound of CI < –8.8 for PCL-M and < –5.0 for BDI)
d90% Confidence interval used to evaluate non-inferiority
eTreatment difference not calculated in the study due to high levels of attrition